Prestige Consumer Healthcare Inc. $PBH Shares Bought by Citigroup Inc.

Key Points

• Citigroup Inc. increased its stake in Prestige Consumer Healthcare by 21.6% to own 105,428 shares, which are valued at approximately $9.06 million.
• Prestige Consumer Healthcare reported a 6.6% decrease in quarterly revenue year-over-year, missing analyst expectations with earnings of $0.95 per share compared to a consensus of $1.01.
• Currently, the stock has an average rating of “Hold” from analysts, with a consensus target price of $93.33.

Citigroup Inc. lifted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 21.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 105,428 shares of the company's stock after purchasing an additional 18,759 shares during the quarter. Citigroup Inc. owned about 0.21% of Prestige Consumer Healthcare worth $9,064,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare during the first quarter worth $38,000. McIlrath & Eck LLC increased its stake in Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after acquiring an additional 154 shares during the last quarter. Johnson Financial Group Inc. acquired a new stake in Prestige Consumer Healthcare during the fourth quarter worth $93,000. Costello Asset Management INC acquired a new stake in Prestige Consumer Healthcare during the first quarter worth $112,000. Finally, Sterling Capital Management LLC increased its stake in Prestige Consumer Healthcare by 837.1% during the fourth quarter. Sterling Capital Management LLC now owns 1,593 shares of the company's stock worth $124,000 after acquiring an additional 1,423 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PBH. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Canaccord Genuity Group dropped their price objective on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Stock Up 0.7%

NYSE:PBH traded up $0.4470 during midday trading on Tuesday, reaching $65.3170. The company had a trading volume of 603,368 shares, compared to its average volume of 389,854. The firm has a market capitalization of $3.21 billion, a price-to-earnings ratio of 15.33, a PEG ratio of 2.05 and a beta of 0.43. The stock's fifty day simple moving average is $76.85 and its 200-day simple moving average is $81.54. Prestige Consumer Healthcare Inc. has a 12-month low of $62.95 and a 12-month high of $90.04. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm's quarterly revenue was down 6.6% on a year-over-year basis. During the same period last year, the firm earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.